Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | PTGIR | P43119 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18795927 | 0.89 | PTGIR (0.65) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL1545285 | 0.83 | PLK1 (0.59) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL2646271 | 0.81 | PRSS1 (0.61) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL12348299 | 0.81 | HSD17B10 (0.36) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL9874228 | 0.79 | NPC1 (0.61) | PRSS1PRSS2PRSS3MEN1LMNA | |
| SCHEMBL12332579 | 0.79 | PRSS1 (0.53) | CA1CA2PRSS1PRSS2PRSS3 | |
| Iodide SCHEMBL10985397 | 0.79 | PRSS1 (0.59) | CA1CA2PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL4397004 | 0.79 | PRSS1 (0.59) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL2698404 | 0.78 | ALDH1A1 (0.48) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL17055827 | 0.78 | KMT2A (0.53) | MEN1LMNAMAPTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180172-B1 | [3-(4-Methoxyphenyl)-1,2,4-oxadiazol-5-yl]methanol as an antitumor and antimicrobial compound | King Faisal University (SA) | 2024-12-31 | — | — | US | claimed |
| US-11981647-B1 | 3-(4-methoxyphenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole as an antitumor and antimicrobial compound | King Faisal University (SA) | 2024-05-14 | — | — | US | claimed |
| US-11897850-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-13 | — | — | US | claimed |
| US-11891366-B1 | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-06 | — | — | US | claimed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250091999-A1 | [3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | UNIV KING FAISAL (SA) | 2025-03-20 | — | — | US | disclosed |
| US-12180172-B1 | [3-(4-Methoxyphenyl)-1,2,4-oxadiazol-5-yl]methanol as an antitumor and antimicrobial compound | King Faisal University (SA) | 2024-12-31 | — | — | US | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| WO-2005044797-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-05-19 | — | — | WO | disclosed |
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2004037248-A2 | MODULATION OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ACTIVITY | CAREX SA (FR) | 2004-05-06 | — | — | WO | disclosed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891366-B1 | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound | IL4I1, AADAC, CASP4 | CA1 4830/4885CA2 3688/4885PRSS1 3392/4885 |
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | CA1 3375/4885CA2 1869/4885PRSS1 748/4885 |
| US-20250091999-A1 | [3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | OXA1L, MCL1, CASP3 | CA1 4569/4885CA2 4344/4885PRSS1 4312/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | CA1 354/4885CA2 880/4885PRSS1 1923/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | CA1 4797/4885CA2 4385/4885PRSS1 3296/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | CA1 354/4885CA2 880/4885PRSS1 1923/4885 |
| US-11897850-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound | B3GNT2, IL4I1, NIT2 | CA1 4834/4885CA2 3369/4885PRSS1 4137/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | CA1 4646/4885CA2 4503/4885PRSS1 3626/4885 |
| US-12180172-B1 | [3-(4-Methoxyphenyl)-1,2,4-oxadiazol-5-yl]methanol as an antitumor and antimicrobial compound | OXA1L, MCL1, CASP3 | CA1 4569/4885CA2 4344/4885PRSS1 4312/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | CA1 4646/4885CA2 4503/4885PRSS1 3626/4885 |
| US-11981647-B1 | 3-(4-methoxyphenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole as an antitumor and antimicrobial compound | OXA1L, API5, MCL1 | CA1 4848/4885CA2 4647/4885PRSS1 4534/4885 |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | CA1 1396/4885CA2 1578/4885PRSS1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.